Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Bioinformatics Approaches to Cancer Research

University of Toronto

$100,000.00

A collaborative research program to integrate genomic and proteomic data for the identification of predictive biomarkers in bladder cancer

FY 2008-09

Summary
Bladder cancer is one of the most prevalent and costly cancer types in Canada, with about 6600 new cases and 1750 deaths from this disease each year. Early diagnosis and improved management of bladder cancer would be improved by the availability of biomarkers (proteins or genes) which could be detected in routine urine or blood tests. These biomarkers would help clinicians detect the disease earlier and accurately track its progression, thus allowing them to provide more effective treatment. Currently two distinct approaches are commonly used to identify such biomarkers: identifying a protein or a group of proteins associated with bladder cancer using proteomic research methods (e.g. by mass spectrometry), or identifying a gene or a set of genes associated with the disease using genomic methods (e.g. by gene expression experiments). Since proteins and the genes that encode them are closely related, neither of these approaches is likely to be sufficient on its own. However few efforts have been made to combine these platforms in an integrated and complimentary manner. This is in part due to the vast amount of experimental data generated by each of these disciplines, which requires significant computing power and innovative computer algorithms and statistical methods to extract new knowledge from this data. To address this challenge, we have formed a multi-institution and cross-disciplinary research team that consists of experts in bioinformatics, proteomics, genomics, and clinical cancer pathology. We aim to develop novel bioinformatics methods to bridge the proteomics, genomics and clinical communities and integrate data generated from these complementary disciplines. The research and activities proposed here will set the foundation for long-term collaborations among team members, and contribute new methods and tools for uncovering biomarkers for better diagnosis and treatment of bladder cancer in Canada and around the world.
Program
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
182344
Name
Zhang Zhaolei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Projecttitle
A collaborative research program to integrate genomic and proteomic data for the identification of predictive biomarkers in bladder cancer
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Keyworddelim
Biomarkers; Bionformatics; Bladder Cancer; Cancer Diagnostics; Genomics; Proteomics
Abstract
Bladder cancer is one of the most prevalent and costly cancer types in Canada, with about 6600 new cases and 1750 deaths from this disease each year. Early diagnosis and improved management of bladder cancer would be improved by the availability of biomarkers (proteins or genes) which could be detected in routine urine or blood tests. These biomarkers would help clinicians detect the disease earlier and accurately track its progression, thus allowing them to provide more effective treatment. Currently two distinct approaches are commonly used to identify such biomarkers: identifying a protein or a group of proteins associated with bladder cancer using proteomic research methods (e.g. by mass spectrometry), or identifying a gene or a set of genes associated with the disease using genomic methods (e.g. by gene expression experiments). Since proteins and the genes that encode them are closely related, neither of these approaches is likely to be sufficient on its own. However few efforts have been made to combine these platforms in an integrated and complimentary manner. This is in part due to the vast amount of experimental data generated by each of these disciplines, which requires significant computing power and innovative computer algorithms and statistical methods to extract new knowledge from this data. To address this challenge, we have formed a multi-institution and cross-disciplinary research team that consists of experts in bioinformatics, proteomics, genomics, and clinical cancer pathology. We aim to develop novel bioinformatics methods to bridge the proteomics, genomics and clinical communities and integrate data generated from these complementary disciplines. The research and activities proposed here will set the foundation for long-term collaborations among team members, and contribute new methods and tools for uncovering biomarkers for better diagnosis and treatment of bladder cancer in Canada and around the world.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, Zhaolei; Evans, Kenneth R; Feilotter, Harriet E; Squire, Jeremy A; Van Der Kwast, Theodorus H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~